Based on the Zymeworks Inc. Common Stock stock forecast from 2 analysts, the average analyst target price for Zymeworks Inc. Common Stock is USD 13.00 over the next 12 months. Zymeworks Inc. Common Stock’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Zymeworks Inc. Common Stock is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Zymeworks Inc. Common Stock’s stock price was USD 14.20. Zymeworks Inc. Common Stock’s stock price has changed by -4.76% over the past week, +9.82% over the past month and +74.45% over the last year.
No recent analyst target price found for Zymeworks Inc. Common Stock
No recent average analyst rating found for Zymeworks Inc. Common Stock
Company Overview Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. Read Less
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase ...Read More
Frequently Asked Questions About Zymeworks Inc. Common Stock (ZYME) Stock
Based on ratings from 2 analysts Zymeworks Inc. Common Stock's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on ZYME's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ZYME is USD 13.00 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 10.
ZYME stock's Price/Earning ratio is 2.83.
Our analysis grades ZYME stock's Price / Earning ratio at F. This means that ZYME stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ZYME may be fairly valued for its sector
The last closing price of ZYME's stock was USD 14.20.
The most recent market capitalization for ZYME is USD 0.98B.
Based on targets from 2 analysts, the average taret price for ZYME is projected at USD 13.00 over the next 12 months.
This means that ZYME's stock price may go down by -8.45% over the next 12 months.
We can't find any ETFs which contains Zymeworks Inc. Common Stock's stock.
As per our most recent records Zymeworks Inc. Common Stock has 294 Employees.
Zymeworks Inc. Common Stock's registered address is 108 Patriot Drive, Middletown, DE, United States, 19709.
You can get more information about it from Zymeworks Inc. Common Stock's website at https://www.zymeworks.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Zymeworks Inc. Common Stock (ZYME) Stock
Based on ratings from 2 analysts Zymeworks Inc. Common Stock's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on ZYME's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ZYME is USD 13.00 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 10.
ZYME stock's Price/Earning ratio is 2.83.
Our analysis grades ZYME stock's Price / Earning ratio at F. This means that ZYME stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ZYME may be fairly valued for its sector
The last closing price of ZYME's stock was USD 14.20.
The most recent market capitalization for ZYME is USD 0.98B.
Based on targets from 2 analysts, the average taret price for ZYME is projected at USD 13.00 over the next 12 months.
This means that ZYME's stock price may go down by -8.45% over the next 12 months.
We can't find any ETFs which contains Zymeworks Inc. Common Stock's stock.
As per our most recent records Zymeworks Inc. Common Stock has 294 Employees.
Zymeworks Inc. Common Stock's registered address is 108 Patriot Drive, Middletown, DE, United States, 19709.
You can get more information about it from Zymeworks Inc. Common Stock's website at https://www.zymeworks.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZYME !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
